RT Journal Article
SR Electronic
T1 Real world hypertension treatment patterns analysis identifies putative gaps and risk-associated patterns
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.28.20169623
DO 10.1101/2020.10.28.20169623
A1 Sricharan Bandhakavi
A1 Jasmine M. McCammon
A1 Sunil Karigowde
A1 Zhipeng Liu
A1 Xianglian Ni
A1 Farbod Rahmanian
YR 2020
UL http://medrxiv.org/content/early/2020/10/30/2020.10.28.20169623.abstract
AB Objective Although treatment patterns’ analyses at scale can provide insights into associated health outcomes, they remain relatively uncharacterized for most chronic diseases, including hypertension (HTN). To address this gap, we analyzed HTN treatment patterns among US health-insured patients.Materials and Methods New (n = 200,786) or all (n = 4.1 million) HTN patients were identified from 2015, 2016 enrollments in a nationwide administrative claims’ database and compared for HTN-specific treatment (Rx) choices, Rx count, and distinct rounds of treatment options (ROTO), respectively. Selected treatment patterns were risk-assessed using predictive modeling and/or literature-based recommendations.Results For 2016, ACE inhibitors/ARBs were most frequent choices in new HTN patients’ vs more diverse Rx-choices among all HTN patients. All HTN patients had ∼3-fold and ∼5-fold-higher prevalence of (same-year) polytherapy and Rx interventions, respectively.New HTN patients with ≥2 rounds of treatment options (vs single/initial round) were associated with ∼5-fold or higher predicted HTN complications’ risk (p-value < 0.0001). All HTN patients with ≥3 rounds of treatment options (vs single/initial round) had 3.8-fold higher next-year HTN complications’ risk (p-value < 0.0001). Co-morbidities/persistence of ≥3 rounds of treatment options over 2 years further increased these odds and total medications/chronic disease score correlated with ROTO counts.Discussion ∼95% of new HTN patients in 2016 did not start treatment with current literature-recommended first option, Thiazides. Assuming “sticky” prescription patterns, opportunity exists to improve (current) initial HTN treatments. Additionally, ROTO counts can inform HTN complications’ risk/management thereof.Conclusion We highlight opportunities to improve initial HTN treatments and treatment patterns associated with higher risk among HTN patients.Competing Interest StatementAll authors are employees of Geneia LLC.Funding StatementNo external funding was receivedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Geneia Research Ethics Committee determined no ethics approval requiredAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data used for this manuscript are commercially licensed from CCAE database and not publicly available.